Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival by Victor J. Weigman et al.
PRECLINICAL STUDY
Basal-like Breast cancer DNA copy number losses identify genes
involved in genomic instability, response to therapy,
and patient survival
Victor J. Weigman • Hann-Hsiang Chao • Andrey A. Shabalin • Xiaping He •
Joel S. Parker • Silje H. Nordgard • Tatyana Grushko • Dezheng Huo •
Chika Nwachukwu • Andrew Nobel • Vessela N. Kristensen • Anne-Lise Børresen-Dale •
Olufunmilayo I. Olopade • Charles M. Perou
Received: 2 October 2011 / Accepted: 4 October 2011 / Published online: 3 November 2011
 The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract Breast cancer is a heterogeneous disease with
known expression-defined tumor subtypes. DNA copy
number studies have suggested that tumors within gene
expression subtypes share similar DNA Copy number
aberrations (CNA) and that CNA can be used to further sub-
divide expression classes. To gain further insights into the
etiologies of the intrinsic subtypes, we classified tumors
according to gene expression subtype and next identified
subtype-associated CNA using a novel method called
SWITCHdna, using a training set of 180 tumors and a val-
idation set of 359 tumors. Fisher’s exact tests, Chi-square
approximations, and Wilcoxon rank-sum tests were per-
formed to evaluate differences in CNA by subtype. To assess
the functional significance of loss of a specific chromosomal
region, individual genes were knocked down by shRNA and
drug sensitivity, and DNA repair foci assays performed.
Most tumor subtypes exhibited specific CNA. The Basal-
like subtype was the most distinct with common losses of the
regions containing RB1, BRCA1, INPP4B, and the greatest
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overall genomic instability. One Basal-like subtype-associ-
ated CNA was loss of 5q11–35, which contains at least three
genes important for BRCA1-dependent DNA repair
(RAD17, RAD50, and RAP80); these genes were predomi-
nantly lost as a pair, or all three simultaneously. Loss of two
or three of these genes was associated with significantly
increased genomic instability and poor patient survival.
RNAi knockdown of RAD17, or RAD17/RAD50, in
immortalized human mammary epithelial cell lines caused
increased sensitivity to a PARP inhibitor and carboplatin,
and inhibited BRCA1 foci formation in response to DNA
damage. These data suggest a possible genetic cause for
genomic instability in Basal-like breast cancers and a bio-
logical rationale for the use of DNA repair inhibitor related
therapeutics in this breast cancer subtype.
Keywords Basal-like breast cancer  Genome instability 
BRCA1 pathway  Copy number aberration  Molecular
subtypes  Array CGH
Abbreviations
CNA Copy number aberrations
MTT 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl
tetrazolium bromide
aCGH Array comparative genomic hybridization
HME-CC hTERT-immortalized human mammary
epithelial cell line
ME16C hTERT-immortalized human mammary
epithelial cell line
UMD UNC microarray database
UNC University of North Carolina
USA Samples
NW Norway samples
DWD Distance weighted discrimination
FWER Familywise error rate
pCR Pathologic complete response
T/FAC Taxane, fluorouracil, anthracycline,
cyclophosphamide
Introduction
Previous gene expression profiling studies of human breast
tumors have shaped our understanding that breast cancer is
not one disease, but is in fact many biologically separate
diseases. A classification of tumors by expression profiling
into five distinct groups (Luminal A, Luminal B, HER2-
enriched, Basal-like, and Claudin-low subtypes) has added
prognostic and predictive value to the existing repertoire
of biomarkers for breast cancer [1–6]. For many cancers,
improper maintenance of genome stability is a major cause
of tumorigenesis and thus, the characterization of the tumor
genomic DNA landscape is an important avenue of
investigation [7]. Array comparative genome hybridization
(aCGH) studies of tumor copy number states have dem-
onstrated that tumors with similar gene expression subtypes
may also share similar DNA copy number aberrations
(CNA) [8–12] and that CNA can be used to further sub-
divide expression classes [12]. In breast cancers, genomic
instability-driven tumorigenesis is most prevalent in the
Basal-like subtype (also referred to as triple-negative breast
cancers), where the majority of tumors exhibit many CNA
[9–13]. Identifying the genes that contribute to this insta-
bility phenotype would be useful not only from a biological
perspective, but also possibly as a clinical predictor of
therapeutic response.
Methods
A detailed description of all methods is provided in the
‘‘Supplemental Methods’’ section, while here we provide an
abbreviated methods section for the major new approaches.
Breast cancer patient datasets
For the genomic studies, three patient datasets were used,
each containing gene expression and DNA copy number
microarray data. We combined two sets into a single
training set (n = 180 with expression and copy number) so
that we could have increased statistical power to detect
subtype-specific CNA. The combined training set included
breast tumors from the United States (‘‘UNC’’) (n = 77)
and tumors from Norway (‘‘NW’’) (n = 103). The third
data set (‘‘Jonsson’’) was used as a validation/testing set
(n = 359) [14]. All samples were collected using IRB-
approved protocols. Data is available from Gene Expres-
sion Omnibus series GSE10893. Sample information
including clinical data, subtype, source, GEO Sample ID,
and overlap with copy number information can be found in
Supplemental Table 1.
Assessment of tumor genomic DNA copy number
changes
77 UNC and 103 NW samples had normal and tumor DNA
samples each assayed using the Infinium Human-1 109K
BeadChip (Illumina, San Diego, CA, USA). Sample infor-
mation is provided in Supplemental Table 1 and LogR
(A?B signal) values can be found on GEO series
GSE10893, platform GPL8139. To determine regions of
copy number aberration (CNA), we developed a new anal-
ysis method that is a modification of the SupWald method
[15, 16]; we created an R suite of functions called
‘‘SWITCHdna’’, which can identify breakpoints in aCGH
data. SWITCHdna detects transition points that maximize
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the F statistic and have regions on either side of the break-
point that are larger than the user-defined range. Following
detection of the transition points, a segment average value
and corresponding z-score are determined, along with the
number of observations used. The end results are the iden-
tification of segments of CNA, along with a quantitative
value for that copy number change (i.e., loss or gain).
A significance filter is applied to the raw SWITCHdna-
identified segments in order to reduce noise and increase
the probability of identifying biologically relevant regions.
All subsequent plots and tables were produced after
applying this significance filter to our data. SWITCHdna is




Using the cnaGENE function of SWITCHdna, the segment
output file was converted into an indicator matrix, where for
each sample, each gene’s copy state was represented as
-1 = loss, 0 = no change, 1 = gain. For each subtype, the
counts of gains and losses were compared versus all other
samples in order to identify subtype-specific CNAs.
A Fisher’s exact test was performed on the subtype versus rest
counts for each gene. The resulting P values were adjusted by
the Benjamini-Hochberg method [18] to correct for multiple-
hypothesis testing and genes with P values\0.05 were then
gathered for each subtype. Regions within the cytobands of
localized CNA were determined by the significant genes
found within each cytoband (Supplemental Table 2).
Supplemental methods
Numerous additional methods, and more detail on
SWITCHdna is provided in the Supplemental Methods
section. These methods include details on the cell lines
used, RNAi knockdown experiments, and other cell biol-
ogy type experiments performed here.
Results
Identifying subtype-specific regions of
copy number aberration
To identify CNA that might be causative of Basal-like
breast cancers, we assembled a dataset of 180 tumors with
Agilent gene expression microarrays and Illumina 109,000
SNP marker DNA copy number microarrays (UNC-NW).
We classified each tumor into one of five previously
defined expression subtypes using the published intrinsic
subtypes (i.e., PAM50) and Claudin-low subtype predictors
[5, 6]. To identify regions of copy number gain/loss, we
developed a new segmenting method called ‘‘SWITCH-
dna’’ (Sup Wald Identification of copy CHanges in dna).
Specifics of the SWITCHdna method can be found in the
‘‘Supplemental Methods’’ and at https://genome.unc.edu/
pubsup/SWITCHdna/.
SWITCHdna-identified regions/segments of copy num-
ber gains and losses in each tumor, which were then
aggregated based on subtype to look at the frequency of
each copy number event in each subtype and identify
regions specific to each subtype (Fig. 1; Supplemental
Table 2). A heat map display of the copy number data is
provided in Supplemental Fig. 1. A number of new find-
ings were observed including the first aCGH character-
ization of the Claudin-low subtype (Fig. 1b). Despite its
high grade and similarity to Basal-like tumors [5, 6],
Claudin-low tumors showed few copy number changes,
which may correspond to the previously described ER-
negative and copy number neutral tumor subtype reported
in Chin et al. [19]. In addition, human Claudin-low cell
lines, which are often called ‘‘Basal B’’ lines, also have a
similar flat copy number profile of showing very few
chromosomal abnormalities [20].
We next searched for CNA occurring specifically within
each subtype (Fig. 1a–f, black shading). The Basal-like
subtype had the most subtype-specific events (Fig. 1a, g)
including the previously described amplicon at 10p con-
taining MAP3K8, ZEB1, and FAM107B [13, 21, 22], 16q
loss [23], deletion of 5q11–35 [10], and deletion of 4q. This
last region contains INPP4B, which has recently been
identified as a potential tumor suppressor involved in the
inhibition of PI3K signaling [24] and that is selectively lost
in Basal-like/Triple-negative breast cancers [25].
Basal-like tumors have previously been observed to
have copy number loss and/or low expression of genes
involved in BRCA1 DNA damage repair [26], and we
noted that loss of 5q11–5q35 would delete several genes
involved in BRCA1-dependent DNA repair including
RAD17, RAD50 [27], and RAP80 (Fig. 1h). Closer exam-
ination of the pattern of loss of these genes revealed that
each gene was rarely lost as an individual event, but pre-
dominantly lost as a pair or triplet (Table 1a). These dou-
blet or triplet losses occurred at the highest rates in the
Basal-like subtype, but also occurred less frequently in the
HER2-enriched subtype. These paired or triplet losses were
not simply due to loss of the entire chromosomal arm as
[65% of the analyzed tumors did not show a loss pattern
indicative of such an event and several samples had
intervening regions of normal copy number. Loss of
5q11–35 was also found to statistically co-occur with CNA
of other regions including 10p amplification (*50%),
INPP4B/4q31.21 loss (*40%), PTEN/10q23.31 loss
(*40%), BRCA1/17q21 loss (*50%), and most frequently
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loss of RB1/13q14.2 (*80%) (Table 1e), which are genes/
regions that have all previously shown to be associated
with Basal-like breast cancers.
In order to validate these subtype-specific findings
observed in the UNC?NW dataset, we classified the samples
in Jonsson et al. [14] according to PAM50 and Claudin-low
subtype predictors and performed similar supervised analy-
ses using their BAC-based DNA copy number data; very
similar associations between CNA and subtypes were
observed (Table 2). Jonsson et al. identified six unique tumor
subtypes based upon CNA landscapes, which we determined
were highly correlated with our expression-defined intrinsic
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Fig. 1 Copy number frequency plots from SWITCHdna show
regions of aberrations shared by members of the same subtype. Gray
shading indicates regions of change with the y-axis representing
frequency of aberration at each site within each subtype. Regions in
black were statistically associated with a particular subtype and
remained significant after Benjamini-Hochberg correction. Regions
below the center (negative values) represent losses, and areas above
the center (positive values) indicate gains. a Basal-like, b Claudin-
low, c HER2-enriched, d Luminal A, e Luminal B, and f Normal-like.
g Expanded view of the Basal-like copy number landscape. INPP4B,
MAP3K8, FAM107B, and ZEB1, each in Basal-like specific regions of
CNA, are marked. BRCA1, BRCA2, PTEN, RB1, and TP53, are genes/
regions that were frequently, but not specifically, lost in the Basal-like
subtype, and KRAS, which is frequently but not specifically gained in
the Basal-like subtype, are also noted. The dashed horizontal lines
indicate 50% gain or loss. h Enlarged view of the Basal-like
chromosome 5q region showing the location of RAD17, MSH3,
RAD50, and RAP80. Loss frequency is indicated on the y-axis and the
level of 50% loss is highlighted by the horizontal line
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Table 1 Frequency of copy number alterations data for the UNC-Norway combined dataset for selected (a) deletions, (b) amplifications,
(c) average number of changes, (d) % Tumor Cellularity, and (e) co-occurrences














No. % No. % No. % No. % No. % No. %
(a) Deletions
No 5q Genes Lost 13 32.5 11 73.3 11 52.4 42 80.8 32 80.0 10 83.3 \0.001 119 66.1
5q13.2 (RAD17) 5 12.5 1 6.7 1 4.8 4 7.7 2 5.0 1 8.3 \0.001 14 7.8
5q31.1 (RAD50) 1 2.5 0 0.0 1 4.8 0 0.0 2 5.0 0 0.0 \0.001 4 2.2
5q35.2 (RAP80) 1 2.5 1 6.7 0 0.0 2 3.8 2 5.0 0 0.0 0.001 6 3.3
RAD17/RAD50 5 12.5 2 13.3 3 14.3 2 3.8 0 0.0 0 0.0 \0.001 12 6.7
RAD17/RAP80 1 2.5 0 0.0 0 0.0 0 0.0 1 2.5 1 8.3 \0.001 3 1.7
RAD50/RAP80 0 0.0 0 0.0 0 0.0 1 1.9 1 2.5 0 0.0 \0.001 2 1.1
RAD17/RAD50/RAP80 14 35.0 0 0.0 5 23.8 1 1.9 0 0.0 0 0.0 \0.001 20 11.1
10q23.31 (PTEN) 9 22.5 1 6.7 5 23.8 12 23.1 12 30.0 2 16.7 0.6 41 22.8
13q14.2 (RB1) 18 45.0 3 20.0 7 33.3 11 21.1 33 82.5 4 33.3 \0.001 76 42.2
17p13.1 (TP53) 20 50.0 6 40.0 12 57.1 18 34.6 20 50.0 4 33.3 0.4 80 44.4
17q21 (BRCA1) 17 42.5 2 12.5 11 52.4 11 21.2 7 17.5 3 25.0 0.01 51 28.3
13q12.1 (BRCA2) 12 30.0 3 18.8 5 23.8 8 15.4 21 52.5 3 25.0 0.01 52 28.9
4q31.21 (INPP4B) 16 40.0 1 11.1 1 4.8 6 11.5 4 10.0 1 8.3 0.002 29 16.1
(b) Amplifications
17q12 (ERBB2) 9 22.5 2 13.3 12 57.1 9 17.3 15 37.5 2 16.7 0.007 49 27.2
12p12.1 (KRAS) 14 35.0 4 26.7 5 23.8 9 17.3 9 22.5 2 16.7 0.5 43 23.9
12q15 (MDM2) 6 15.0 1 6.7 4 19.0 12 23.1 18 45.0 1 8.3 0.01 42 23.3
8q24.21 (MYC) 26 65.0 7 46.7 10 47.6 18 34.6 29 72.5 3 25.0 0.002 93 51.7
10p11.23 (MAP3K8) 16 40.0 1 6.7 6 28.6 3 5.8 3 7.5 2 16.7 \0.001 31 17.2
10p11.22 (ZEB1) 16 40.0 1 6.7 5 23.8 3 5.8 3 7.5 2 16.7 \0.001 30 16.7
10p13 (FAM107B) 20 50.0 1 6.7 5 23.8 4 7.7 6 15.0 1 8.3 \0.001 37 20.6
(c)
Average # of Gains 3943 1543 2970 2847 3885 2326 3192
Average # of Losses 4854 1906 3347 2560 4634 2891 3590
Total # of Aberrations 8797 3450 6317 5408 8519 5218 6782
Average # of Segments 194 143 223 150 222 139 183
Segment Length (kb 14988 20421 13068 19424 13113 21062 15923
(d)
% Tumor Cellularity (ASCAT) 52.5 38.4 38.2 53.0 50.2 38.1 48.4
% Tumor Purity (genoCNA) 75.0 78.0 79.5 68.0 68.0 70.0 71.0
(e) Co-occurrence of 5qb loss with additional gene loss
N No. % P-Valuec
10q23.31 (PTEN) Loss 32 14 43.8 \0.001
13q14.2 (RB1) Loss 32 26 81.3 \0.001
17q21 (BRCA1) Loss 32 17 53.1 \0.001
10p Amplicon 32 15 46.9 \0.001
17p13.1 (TP53) Loss 32 19 59.4 0.08
4q31.21 (INPP4B) Loss 32 16 50.0 \0.001
Values are presented in ‘Count (%)’ format. Specific counts are given for individual deletions or co-deletions, with each sample only classified into one category. c
Counts for average gains/losses for each subtype. Total number of aberrations is the sum of all individual gene gains and losses. Average segment number and length
were calculated from the SWITCHdna generated segments for each sample within each subtype. d % Tumor Cellularity generated by ASCAT algorithm or
genoCNA algorithm. e Rates of co-occurrence of 5q cluster loss with other gene alterations are shown (N refers to the number of total samples with 5q loss). Fisher’s
exact tests or Chi-square approximations were done to determine if the rates of occurrence, or co-occurrence, were at statistically significant levels
a Chi-square approximation
b RAD17?RAD50 loss OR RAD17?RAD50?RAP80 loss
c Fisher’s exact test
Breast Cancer Res Treat (2012) 133:865–880 869
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Table 2 Frequency of copy number alterations data for the Jonsson dataset [14] for selected (a) deletions, (b) amplifications, (c) average number
of changes, and (d) co-occurrences














No. % No. % No. % No. % No. % No. %
(a) Deletions
No 5q Genes Lost 15 24.6 29 67.4 28 58.3 107 90.7 44 80.0 26 76.5 \0.001 249 69.9
5q13.2 (RAD17) 9 14.8 4 9.3 3 6.3 3 2.5 5 9.1 3 8.8 \0.001 27 7.6
5q31.1 (RAD50) 4 6.6 0 0.0 2 4.2 3 2.5 3 5.5 1 2.9 \0.001 13 3.7
5q35.2 (RAP80) 0 0.0 0 0.0 0 0.0 2 1.7 0 0.0 1 2.9 \0.001 3 0.8
RAD17/RAD50 16 26.2 2 4.7 12 25.0 2 1.7 2 3.6 2 5.9 \0.001 36 10.1
RAD17/RAP80 3 4.9 1 2.3 0 0.0 0 0.0 0 0.0 0 0.0 \0.001 4 1.1
RAD50/RAP80 2 3.3 0 0.0 1 2.1 0 0.0 1 1.8 0 0.0 \0.001 4 1.1
RAD17/RAD50/RAP80 12 19.7 7 16.3 2 4.2 1 0.8 0 0.0 1 2.9 \0.001 23 6.5
10q23.31 (PTEN) 21 34.4 10 23.3 9 18.8 14 11.9 17 30.9 2 5.9 \0.001 73 20.5
13q14.2 (RB1) 33 54.1 16 37.2 13 27.1 32 27.1 31 56.4 8 23.5 \0.001 133 37.4
17p13.1 (TP53) 21 34.4 6 14.0 17 35.4 33 28,0 19 34.5 11 32.4 0.2 107 30.1
17q21 (BRCA1) 19 31.1 6 14.0 7 15.2 12 10.3 5 9.1 5 14.7 \0.001 54 15.2
13q12.1 (BRCA2) 22 36.1 13 30.2 12 26.1 26 22.2 30 54.5 7 20.6 \0.001 110 30.9
4q31.21 (INPP4B) 29 47.5 14 32.6 16 34.8 13 11.1 11 20.0 2 5.9 \0.001 85 23.9
(b) Amplifications
17q12 (ERBB2) 9 14.8 5 11.6 31 64.6 23 19.5 17 30.9 6 17.6 \0.001 91 25.6
12p12.1 (KRAS) 12 19.7 7 16.3 3 6.5 3 2.5 10 18.2 0 0.0 \0.001 35 9.8
12q15 (MDM2) 2 3.3 4 9.3 7 15.2 13 11.1 17 30.9 0 0.0 \0.001 43 12.1
8q24.21 (MYC) 42 68.9 19 44.2 22 47.8 48 41.0 44 80.0 14 41.2 \0.001 189 53.1
10p11.23 (MAP3K8) 16 26.2 8 18.6 7 14.6 6 5.1 8 14.5 1 2.9 0.001 46 12.9
10p11.22 (ZEB1) 16 26.2 8 18.6 8 16.7 6 5.1 8 14.5 1 2.9 \0.001 47 13.2
10p13 (FAM107B) 29 47.5 10 23.3 6 12.5 6 5.1 11 20.0 3 8.8 \0.001 65 18.3
c)
Average # of Gains 2853 2169 2481 1963 3281 1469 4675
Average # of Losses 5089 3171 3523 2430 3872 2395 6597
Total # of Aberrations 7942 5341 6003 4393 7153 3864 11272
Average # of Segments 167 130 134 97 129 93 122
Segment Length (kb) 16522 21289 20573 28542 21462 29841 22610
(d) Co-occurrence of 5qb loss with additional gene loss
N No. % P-Valuec
10q23.31 (PTEN) Loss 67 28 41.8 \0.001
13q14.2 (RB1) Loss 67 39 58.2 \0.001
17q21 (BRCA1) Loss 67 24 35.8 \0.001
10p Amplicon 67 15 22.4 0.02
17p13.1 (TP53) Loss 67 29 43.3 0.01
4q31.21 (INPP4B) Loss 67 31 46.3 \0.001
Values are presented in Count (%) format. Specific counts are given for individual deletions or co-deletions, with each sample only classified into
one category. c Counts for average gains/losses for each subtype. Total number of aberrations is the sum of all individual gene gains and losses.
Average segment number and length were calculated from the SWITCHdna generated segments for each sample within each subtype. d Rates of
co-occurrence of 5q cluster loss with other gene alterations are shown (N refers to the number of total samples with 5q loss). Fisher’s exact tests
or Chi-square approximations were done to determine if the rates of occurrence, or co-occurrence, were at statistically significant levels
a Chi-square approximation
b RAD17?RAD50 loss OR RAD17?RAD50?RAP80 Loss
c Fisher’s exact test
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subtypes (P value\0.001, Table 3); importantly, there was
high overlap between our Basal-like subtype and their Basal-
complex phenotype, both of which showed the frequent loss
of 5q11–35 and amplification of 10p.
Increased genomic instability of tumors associated
with loss of specific regions/genes
To objectively assess ‘‘genomic instability’’, we calculated a
loss/normal/gain value for every gene using the SWITCH-
dna assigned copy number states, and calculated the levels of
genomic instability by subtype using the average number of
gains/losses per sample on a gene by gene basis. The Basal-
like subtype was the most prone to aberrations, while the
Claudin-low and Luminal A subtypes showed the lowest
number of gene-based CNA (Table 1c). To control for a
large number of genes being gained or lost by a large single
genomic aberration event (i.e., whole chromosome loss), we
also calculated the average number of SWITCHdna-defined
segments and their length for each subtype, as more genomic
breaks will result in more segments. The subtypes that had
greater numbers of gene aberrations were also the same ones
that had more SWITCHdna segments of shorter average
length (Table 1c). Thus, the increased number of aberrant
gene-based events in the copy number unstable subtypes was
due to more frequent aberrations in the genome, rather
than as a large number of genes gained or lost by a few large-
in-size aberration events.
Tumors with loss of PTEN/10q23.31, RB1/13q14.2, or
TP53/17p13.1, or amplification of the 10p region were also










Basal 7 4 4 3 1 42
LumA 18 42 15 10 31 2
Claudin 11 4 8 4 3 13
LumB 11 36 3 2 1 2
Her2 1 9 3 30 0 5
Normal-like 4 10 5 2 10 3
Subtype classifications using both the original labels in the Jonsson dataset [14] using copy number defined subtypes, versus PAM50 plus
Claudin-low gene expression subtypes is shown. P value determined by Chi-square approximation
P-value \ 0.001
Table 4 Examination of possible correlations between the specific CNA and overall genomic instability
Average gain Average loss Average total
Average amount of CNA by event and class in combined UNC/Norway dataset
All samples mean (n = 180) 3,192 3,590 6,783
All samples median (n = 180) 2,790 3,230 6,560
RAD17 ? RAD50 (n = 12) 3,948 (P = 0.1) 5,614 (P = 0.0004*) 9,562 (P = 0.003*)
RAD17 ? RAD50 ?/- RAP80 (n = 32) 4,451 (P = 0.0002*) 6,681 (P \ 0.00001*) 11,131 (P \ 0.00001*)
RAD17 ? RAD50 ? RAP80 (n = 20) 4,752 (P = 0.0002*) 7,320 (P \ 0.00001*) 12,073 (P \ 0.00001*)
Other (n = 148) 2,920 2,922 5,842
10q23.31 (PTEN) loss (n = 31) 4,202 (P = 0.009*) 6,169 (P \ 0.00001*) 10,371 (P \ 0.00001*)
No 10q23.31 (PTEN) loss (n = 149) 2,982 3,054 6,036
13q14.2 (RB1) loss (n = 66) 4,127 (P = 0.00002*) 5,638 (P \ 0.00001*) 9,765 (P \ 0.00001*)
No 13q14.2 (RB1) loss (n = 114) 2,652 2,404 5,056
17p13.1 (TP53) loss (n = 80) 3,900 (P = 0.00008*) 4,8578 (P \ .00001*) 8,757 (P \ 0.00001*)
No 17p13.1 (TP53) loss (n = 100) 2,627 2,576 5,203
10p Amplicon (n = 34) 5,016 (P \ 0.00001*) 5,232 (P = 0.0002*) 10,248 (P \ 0.00001*)
No 10p Amplicon (n = 146) 2,768 3,208 5,975
The average numbers of CNAs for gains, losses, or both, are shown for the entire dataset and within sets of tumors with a given copy number
alteration (5q, PTEN/10q23.31, RB1/13q14.2, TP53/17p13.1, and 10p). A Wilcoxon-rank sum test was performed to see if the rate of copy
number aberration between each group (Pairwise: Aberration vs. Other, or No Aberration) was significantly different (*)
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found to have high rates of total gene-based CNA com-
pared to tumors without loss of these genes (Table 4). Loss
of 5q11–35 was also associated with the highest numbers
of CNA, with the greatest instability seen when all three
DNA repair genes were lost.
Low expression of genes residing in Basal-like regions
correlates with poor survival and predicts therapeutic
response
To determine if these DNA loss events also impacted gene
function, we determined whether the mRNA levels of candi-
date genes contained within these regions correlated with
DNA loss. The expression of ten genes selected based on their
associations with the basal-like subtype, or breast cancer in
general, was evaluated. Most showed significantly lower
mRNA expression when the genomic DNA was lost including
RAD17, RAD50, RAP80, MSH3, RB1, PTEN, BRCA1, and
INPP4B (Fig. 2); these data suggest that these losses have
functional consequences (noting that only TP53 and BRCA2
did not show in cis correlation between expression and copy
number). It is also of note that MSH3 (a gene involved in DNA
mismatch repair), located within the 5q11–35 loss region
(between RAD17 and RAD50, Fig. 1h), and it also showed
reduced mRNA expression when lost and low expression
within Basal-like tumors in general (Figs. 2, 3e). In addition,
the mRNA expression levels of RAD17, RAD50, MSH3,
RAP80, INPP4B, and PTEN were lowest in the Basal-like
subtype (Fig. 3, UNC337 expression dataset [5]); thus loss of
5q11–35 likely affects multiple aspects of DNA repair.
Using patient survival data from two additional data sets
containing gene expression data (UNC337 [5] and NKI295
[28]), Kaplan–Meier analysis showed that the low average
expression of RAD17?RAD50 was associated with worse
outcomes compared to high expression (Fig. 4a). A similar
trend was observed with INPP4B, mirroring previous
observations (Fig. 4b) [24]. RAD17?RAD50 expression
was also examined for treatment effects using the Hess et al.
[29] data set, which examined T/FAC neoadjuvant chemo-
therapy responsiveness across 130 breast cancer patients.
Low expression of RAD17?RAD50 was correlated with
pathological complete response (pCR) (ANOVA P value
\0.0001). This finding may be due to the association
between low expression of RAD17?RAD50 and Basal-like
tumors, as Basal-like tumors have also been shown to have
high neoadjuvant chemotherapy pCR rates [30, 31].
Knockdown of RAD17±RAD50 affects sensitivity
to chemotherapeutics and BRCA1 foci formation
Given the involvement of RAD17, RAD50, and RAP80 in
the BRCA1-DNA repair pathway, we determined whether
disruption of these genes via RNAi knockdown would lead
to changes in sensitivity to drugs whose mechanism of
action has already been linked to BRCA1 loss like carbo-
platin/cisplatin [32, 33] and PARP inhibitors [34, 35].
RAD17 was stably knocked down with shRNA in the
HME-CC cell line (an hTERT-immortalized Human
Mammary Epithelial Cell) [36] and knockdown was con-
firmed by Western blotting (Fig. 5a). HME-CC cells with
RAD17 knockdown exhibited increased sensitivity to
ABT-888 (PARPi) and carboplatin (Fig. 5c). No difference
in paclitaxel sensitivity was observed, which was used as a
non-DNA-damaging agent control. A RAD50 knockdown
line did not exhibit any change in sensitivity to ABT-888
and had a paradoxical increase in resistance to carboplatin.
We next emulated the most common in vivo co-occurring
loss by generating a double knockdown of RAD17 and
RAD50, which showed the greatest increased sensitivity to
ABT-888 and carboplatin (Fig. 5c). Similar results were
observed when this experiment was repeated in ME16C
cells, a second hTERT-immortalized human mammary
epithelial cell line (Supplemental Fig. 2).
In order to assess the effects of RAD17/RAD50 loss on
BRCA1-dependent DNA repair, we performed a DNA repair
foci formation assay on the control and RAD17?RAD50
double knockdown line. Using anti-BRCA1 protein immu-
nofluorescence, and automated foci counting within gemi-
nin-positive cells, we observed a significant decrease in the
number of BRCA1-containing DNA repair foci in the double
knockdown line when treated with ionizing radiation or
ABT888 versus control (Fig. 6); cells were simultaneously
stained for geminin in order to control for differences in
proliferation as described by Graeser et al. [37, 38]. These
data suggest that loss of RAD17 and/or RAD50 may impair
BRCA1 function, and could contribute to increased sensi-
tivity to DNA-damaging agents.
Discussion
The presence of distinct breast cancer expression subtypes
suggests different underlying genetic events may be driv-
ing each subtype. To address this hypothesis, we used 180
diverse tumors and performed supervised analyses of their
tumor DNA copy number landscape and identified subtype-
specific copy number events. Many studies have identified
numerous regions of gain and loss in human breast tumors
[9, 10, 14, 23, 39]; however, most did not specifically
search for regions uniquely associated with specific
intrinsic subtypes. Some previous attempts were made to
identify basal-like specific CNA [10, 22] and we observed
a number of the same findings. We take these previous
findings as validation of our identified regions, and we
build and expand upon these here, along with the addition
of functional studies.













































































































































































































Fig. 2 Gene expression values for RAD17, RAD50, RAP80, MSH3, BRCA1, BRCA2, PTEN, RB1, TP53, and INPP4B in the UNC-Norway
dataset (n = 180) separated by copy number status (DNA copy number loss vs no loss). P values determined by ANOVA test
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Overall, we identified many subtype-specific CNA and
validated these findings on a second, independent dataset.
Here we have focused on the Basal-like subtype, which
showed by far the greatest number of subtype-specific
CNA and were the most genomically unstable as deter-
mined by the sheer number of CNA, a feature which has
been observed in the past [9]. Basal-like tumors also
showed consistent loss of 4q (which harbors INPP4B and
FBXW7), and 5q11–35, which contains many DNA repair
genes. Basal-like tumors are known to be associated with
BRCA1-pathway dysfunction in that 80–90% of BRCA1
mutation carriers, if and when they develop breast cancer,
develop Basal-like tumors [3, 40, 41]; however, in most
sporadic Basal-like tumors, the BRCA1 gene appears nor-
mal in sequence [42]. The loss of 5q11–35 may provide an
alternative means to impair BRCA1-pathway function and
explain why despite many Basal-like patients having nor-
mal BRCA1 gene/protein, high levels of genomic insta-
bility and a ‘‘BRCAness’’ phenotype are observed in Basal-
like tumors. Previous evidence indicates a link between
genes involved in BRCA1 DNA damage control and genes
that are deleted and downregulated in Basal-like cancers,
lending further credence to our hypothesis [26].
In order to expand our understanding of the relationship
between the Basal-like subtype and impaired BRCA1-
pathway function, we pursued functional studies by RNAi-
mediated knockdown of two members of the pathway,
RAD17 and RAD50, in order to emulate the genomic
losses observed in tumors. Besides being members of the
BRCA1-pathway, others have highlighted these genes for
their possible Basal-like association, but without functional
studies [10, 27]. We show here that genetic ablation of
these genes results in impaired DNA repair and increased
drug sensitivity, and furthermore, deletion of RAD17 and
RAD50 in yeast has also been shown to result in increased
sensitivity to DNA-damaging agents including platinum
drugs (http://fitdb.stanford.edu) [43]; these data highlight
that there is an evolutionarily conserved role for these
genes in DNA repair.
By building upon the discovery of the subtype associa-
tion and the deletion phenotypes in yeast, we propose a role
in DNA repair function for the 5q11–35 region. The drug
sensitivity assays show the importance of these genes


















































































































































































































Fig. 3 ANOVA boxplots for individual genes that are commonly lost in Basal-like cancers according to intrinsic subtype determined using the
UNC337 sample set. P values were determined by 2-way ANOVA. a RAD17, b RAD50, c RAP80, d PTEN, e MSH3, and f INPP4B
Fig. 4 Survival analysis according to expression of RAD17?RAD50
and INPP4B. Patients in the UNC337 and NKI295 data sets were
ranked ordered organized by average gene expression values of
a RAD17?RAD50 combined, or b INPP4B. The patients were split
into thirds based upon rank order expression values and Kaplan–
Meier analysis was done on the three groups to examine trends in
relapse-free survival and overall survival. P values determined by log-
rank test
c
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experiments show that their function is mediated through
BRCA1. In addition, from the combination of our genomic
analyses and functional data, it is our hypothesis that the
somatic loss of RAD17, RAD50, and/or RAP80 leads to
impaired BRCA1-pathway function, impaired homologous
recombination mediated DNA repair, and thus, contributes
to overall genomic instability.
There are, however, two caveats to these analyses and
our hypothesis. First, the 5q11–35 loss is a large region that
typically involves [100 genes, therefore, we cannot
definitively say that loss of these three genes is the target of
this deletion, or that these three genes are the most
important targeted genes of this region. Second, a high
frequency of co-occurrence with other DNA chromosomal
losses happens in tumors with 5q11–35 loss; for example,
in *80% of tumors with 5q11–35 loss, RB1/13q14.2 DNA
loss also occurs (and by itself is associated with increased
genomic instability). In addition, *60% of these tumors
show TP53/17p13.1 loss (Table 1, 2). The co-occurrence
of 5q11–35 loss with RB1 and TP53 loss are likely caus-
ative events in Basal-like carcinogenesis (the latter two
being corroborated by mouse studies) [44–46]. Given the
high co-occurrence of chromosome region losses that are
not physically linked, it is impossible to say which one is
the cause of the genomic instability. However, our
hypothesis is that each of these regions harbors genes
needed for maintenance of the genome and that the com-
binatorial loss of 2–3 of these regions is what results in the
genomic instability phenotype seen in Basal-like breast
cancers. In this article, we examine DNA losses, but do
note that it is possible that loss of these same genes could
also occur via methylation, altered microRNA regulation,
and/or somatic mutation, although the last of these has yet
to be found when searching current somatic mutation dat-
abases for RAD17/RAD50/RAP80. Preliminary sequence
analysis of RAD17 and RAD50 (data not shown), as well as
evaluation of previous breast cancer sequencing efforts
[47] and the COSMIC database [48], revealed few, if any,
somatic variants/mutations in these two genes, which is
consistent with the finding that loss of any one gene is
rarely seen; thus, if loss of two or more genes is the target
of this CNA, then somatic mutation of any one gene would
not impart a selective tumorigenic advantage. Therefore,
these data suggest that the target of 5q11–35 loss is two or
more genes in this region, with loss of RAD17 and RAD50
likely contributing to genomic instability.
Conclusions
The gene expression-defined intrinsic subtypes of breast
cancer are mirrored by DNA copy number changes. The
Basal-like subtype is the most distinct in the copy number
landscape world, and these subtype-associated CNA have
clinical implications. If 5q11–35 loss results in impaired
homologous recombination mediated DNA repair, as was
suggested by our in vitro studies and in vivo correlates,
then the loss of this region may sensitize tumors to specific
classes of DNA-damaging agents. Based upon BRCA1
studies in vitro [49, 50] and in vivo [32, 34], these drugs
could include PARP inhibitors and cis/carboplatin. Loss of
RAD17?RAD50 (mRNA and/or genomic DNA) may thus
be a biomarker of chemotherapy responsiveness, which is
supported by our finding of an association for predicting a




















IC50 (95% CI) 
Carboplatin 
IC50 (95% CI) 
Paclitaxel
IC50 (95% CI) 
RAD17 KD (n=6) 262.2 μM (248.3 - 276.0)* 29.6 μM (27.1 - 32.2)* 2.9 nM (2.6 - 3.2)
RAD17 Control 296.3 μM (283.5 - 309.1) 43.3 μM (38.5 - 48.2) 3.0 nM (2.8 - 3.3)
RAD50 KD (n=6) 205.7 μM (196.9 - 214.5) 25.9 μM (22.5 - 29.3)* 5.5 nM (3.8 - 7.2)
RAD50 Control 191.7 μM (176.7 - 206.7) 14.0 μM (11.9 - 16.1) 5.3 nM (3.4 - 7.2)
RAD17-RAD50 Double KD (n=6) 142.4 μM (128.3 - 156.4)* 17.3 μM (15.2 - 19.4)* 3.8 nM (3.5 - 4.1)
RAD17-RAD50 Double Control 244.2 μM (231.4 - 256.9) 31.7 μM (28.5 - 34.9) 4.0 nM (3.6 - 4.3)
* p<0.001
Fig. 5 RNAi knockdown experiments in an immortalized HMEC
(BABE cell line). Western blot analysis showing reduction of RAD17
and RAD50 protein expression in HME-CC a single, or b double
RNAi knockdown lines. (KD knockdown line, C vector control line).
Tubulin staining was performed as a loading control. c Estimated
IC50 with 95% CI for ABT-888, Carboplatin, and Paclitaxel based on
mitochondrial dye-conversion assay. Results are based on the average
of two experiments per condition, each done in triplicate, with
knockdown-control pairs with significant differences in IC50 are
designated with a *
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Fig. 6 BRCA1-mediated DNA
repair foci formation assay.
a Representative images of
BRCA1 foci formation in
RAD17-RAD50 double
knockdown cells and control
cells after treatment with 2.5 Gy
of ionizing irradiation and
20 min recovery (ionizing
radiation), or no treatment
(untreated). b Representative
images of BRCA1 foci
formation in RAD17-RAD50
double knockdown cells and
control cells with 200 lM ABT-
888 (ABT-888), or no treatment
(untreated). Green channel
BRCA1, Red channel Geminin,
Blue channel DAPI images. All
images were taken with a 639
objective and post processed to
300% of their original size.
Automated BRCA1 foci
counting results from each cell
line for c ionizing radiation and
d ABT-888 treatment. Error
bars represent 95% confidence
intervals (*P \ 0.05 of
knockdown relative to control).
P values were calculated from
t tests comparing foci counts in
treated double knockdown cells
versus treated control cells or
untreated double knockdown
cells versus untreated control
cells
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likelihood of achieving a pathological complete response.
We hypothesize that the loss of these DNA repair genes
and the 5q11–35 region, contributes to genomic instability
and mutability, ultimately causing high proliferation rates
and aggressive behaviors. Our integrated studies of gene
expression and genomic DNA copy number have identified
important pathway-based determinants of Basal-like can-
cers and a possible therapeutic biomarker.
All relevant gene expression and copy number data new
to this manuscript can be found in the GEO database under
series GSE10893.
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